Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Pharma News, In Brief

  • News

Executive Summary

Medicare ESRD Performance Measures

You may also be interested in...



Pharmacy-Related Waste Exceeded $403 Billion In 2010 – Express Scripts

Pharmacy benefits manager Express Scripts reported that in 2010, $403 billion in pharmacy-related waste could have been avoided across three areas – the sales channel, generic utilization and nonadherence to medications.

Pharmacy-Related Waste Exceeded $403 Billion In 2010 – Express Scripts

Pharmacy benefits manager Express Scripts reported that in 2010, $403 billion in pharmacy-related waste could have been avoided across three areas – the sales channel, generic utilization and nonadherence to medications.

AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions

The medullary thyroid cancer drug's Risk Evaluation and Mitigation Strategy requires mandatory enrollment and certification of prescribers and pharmacists, which should help ensure the drug is used primarily in patients with symptomatic, progressive disease.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

See All
UsernamePublicRestriction

Register

PS053013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By